PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
暂无分享,去创建一个
T. Holland-Letz | F. L. Giesel | T. Holland-Letz | B. Hadaschik | U. Haberkorn | A. Afshar-Oromieh | C. Zechmann | F. Giesel | H. Linhart | M. Eder | M. Eisenhut | C. Kratochwil | A. Malcher | S. Haufe | A. Afshar-Oromieh | A. Malcher | M. Eder | M. Eisenhut | H. G. Linhart | B. A. Hadaschik | C. Kratochwil | S. Haufe | U. Haberkorn | C. M. Zechmann
[1] N. Bander. Technology Insight: monoclonal antibody imaging of prostate cancer , 2006, Nature Clinical Practice Urology.
[2] N. Bander,et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.
[3] Martin G Pomper,et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). , 2008, Journal of medicinal chemistry.
[4] D. Bostwick,et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.
[5] D. Bostwick,et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.
[6] Victor E Reuter,et al. Prostate-specific membrane antigen expression in regeneration and repair , 2008, Modern Pathology.
[7] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] Martin G Pomper,et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. , 2009, Cancer research.
[9] U. Haberkorn,et al. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[10] M. Aldersley,et al. Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer , 1998, The Lancet.
[11] U. Haberkorn,et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.
[12] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[13] U. Haberkorn,et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer , 2012, EJNMMI Research.
[14] Slave Trajanoski,et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.
[15] George Sgouros,et al. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.